TC
ALPN

TFS Capital’s Alpine Immune Sciences Inc ALPN Stock Holding History

TFS Capital’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,279
Closed -$107K – 919
2016
Q3 		$107K Buy
+3,279
New +$79.8K 0.03% 635

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFS Capital's ALPN Position: Q4 2016 in Review

TFS Capital sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2016, closing a stake of 3,279 shares — an estimated $107K sold.

TFS Capital first reported a position in ALPN in Q3 2016 and held it in 1 quarter. The position peaked at $107K in Q3 2016. 38 funds tracked by Wall St. Rank hold ALPN as of Q4 2016.

  • TFS Capital reported no remaining Alpine Immune Sciences Inc position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 3,279 Alpine Immune Sciences Inc shares in Q4 2016, an estimated $107K.
  • TFS Capital first reported a position in Alpine Immune Sciences Inc in Q3 2016 and held it in 1 quarter.
  • TFS Capital's Alpine Immune Sciences Inc position peaked at $107K in Q3 2016.
  • 38 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.